NCT01367444 - Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 8, 2011

Primary Completion Date

August 16, 2019

Study Completion Date

August 16, 2019

Conditions

Stargardt's Disease

Interventions

DRUG

SAR422459

"Pharmaceutical form: sterile solution, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection"

Trial Locations (5)

33136

Investigational Site Number 840002, Miami

52242

Investigational Site Number 840005, Iowa City

75012

Investigational Site Number 250001, Paris

77030

Investigational Site Number 840004, Houston

97239-3098

Investigational Site Number 840001, Portland